Nuvalent, Inc.

Meels said, I think the efficacy and tox profile of that product is very compelling.

The third quarter also saw the US approval of Jidatro, the first drug from GSK's $10.6 billion acquisition of Nuvalent for ROS1-positive non-small-cell lung cancer.

Meals said, If I had said to you a couple of years ago GSK would have two best-in-class assets and potentially a first-in-class asset in SCLC, representing in total one in five lung cancer patients, I think you probably would have laughed.

That was probably the right thing to do at that point, but now we are really building critical mass.